Aquestive Therapeutics, Inc. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -17.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.10 | $-0.18 | -80.0% | Miss | Q2 FY26 call |
| Q1 FY26 | $-0.14 | $-0.07 | +50.0% | Beat | |
| Q4 FY25 | $-0.13 | $-0.26 | -100.0% | Miss | |
| Q3 FY25 | $-0.13 | $-0.14 | -7.7% | Miss | |
| Q2 FY25 | $-0.18 | $-0.14 | +22.2% | Beat | |
| Q1 FY25 | $-0.17 | $-0.24 | -41.2% | Miss | |
| Q4 FY24 | $-0.14 | $-0.19 | -35.7% | Miss | |
| Q3 FY24 | $-0.12 | $-0.13 | -8.3% | Miss | |
| Q2 FY24 | not reported | $-0.03 | not reported | not reported | |
| Q1 FY24 | $-0.09 | $-0.17 | -88.9% | Miss | |
| Q4 FY23 | $-0.08 | $-0.12 | -50.0% | Miss | |
| Q3 FY23 | not reported | $-0.03 | not reported | not reported |
Back to AQST overview · AQST holders · AQST KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.